Compare TEF & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEF | ILMN |
|---|---|---|
| Founded | 1924 | 1998 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3B | 18.9B |
| IPO Year | 1987 | 2000 |
| Metric | TEF | ILMN |
|---|---|---|
| Price | $4.06 | $129.73 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 15 |
| Target Price | N/A | ★ $117.27 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 11-04-2025 | 02-05-2026 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 4.46 |
| Revenue | ★ $48,832,570,697.00 | $4,288,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.09 | $2.08 |
| P/E Ratio | ★ N/A | $29.49 |
| Revenue Growth | ★ 2.59 | N/A |
| 52 Week Low | $3.89 | $68.70 |
| 52 Week High | $5.72 | $153.06 |
| Indicator | TEF | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 56.42 |
| Support Level | $4.13 | $126.44 |
| Resistance Level | $4.31 | $137.09 |
| Average True Range (ATR) | 0.06 | 3.66 |
| MACD | 0.02 | -0.63 |
| Stochastic Oscillator | 34.74 | 41.28 |
Telefonica is a telecom operator with presence in Spain (where it is the incumbent operator), the UK, Germany, Brazil, and Latin American countries. The company derives more than 30% of its revenue from Spain, close to 20% from Germany, and 20% from Brazil. Its UK operations are held through a joint venture with Virgin Media. For several years Telefonica has been simplifying its corporate structure by selling noncore assets.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.